Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
Location: United States, Pennsylvania, Pittsburgh
Total raised: $425M
Investors 5
| Date | Name | Website |
| - | Population... | population... |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | Access Bio... | accessbio-... |
| 09.08.2022 | GV | gv.com |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.02.2024 | Series A | $75M | - |
| 13.07.2022 | - | $350M | Bain Capit... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 14.02.2024 | Areteia Therapeutics Raises Additional $75M in Series A Fina... | Areteia Therapeutics, a Chapel Hill, NC-based clinical stage biotechnology company, raised additiona... | finsmes.co... |
| 13.02.2024 | Areteia Therapeutics Lands Additional $75M | CHAPEL HILL, NC, Areteia Therapeutics today announced $75 million in additional Series A financing... | vcnewsdail... |
| 18.05.2023 | Areteia Therapeutics Announces Start of Phase III Clinical T... | CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics announced today that the first patients have ... | saturnpart... |